Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study

被引:24
|
作者
Lapi, F. [1 ]
Levi, M. [1 ,2 ]
Simonetti, M. [1 ]
Cancian, M. [3 ]
Parretti, D. [3 ]
Cricelli, I. [1 ]
Sobrero, A. [4 ]
Cricelli, C. [3 ]
机构
[1] Italian Coll Gen Practitioners & Primary Care, Hlth Search, Via Sestese 61, I-50141 Florence, Italy
[2] Univ Florence, Dept Hlth Sci, Florence, Italy
[3] Italian Coll Gen Practitioners & Primary Care, Via Sestese 61, I-50141 Florence, Italy
[4] IRCCS Osped San Martino IST, Med Oncol, Genoa, Italy
关键词
low-dose aspirin; prostate cancer; prevention; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE-2; SURVIVAL; METASTASIS; EXPRESSION; MORTALITY;
D O I
10.1002/ijc.30061
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A growing body of evidence indicates that use of low-dose aspirin (LDA) reduces the risk of certain adenocarcinomas. While there are several and consistent findings on the protective effect of LDA on colorectal and other cancers, few and conflicting evidence is available on prostate cancer (PCa). The aim of this study was to assess whether LDA reduces the incidence rate of PCa. We conducted a nationwide, population-based, retrospective cohort study by using Health Search IMS Health Longitudinal Patient Database (HSD). Patients with ischemic cardio- or cerebrovascular disease (index date) were identified. Time-dependent multivariable Cox proportional hazard models were adopted to estimate Hazard Ratios (HRs) and related 95% confidence intervals (95% CI) of PCa associated with use of LDA. The exposure was lagged by one year to consider the latency of drug effect on the outcome onset. Within a cohort 13,453 patients, the overall incidence rate of PCa was 2.5 per 1,000 person-years. Use of LDA was associated with a decreased incidence rate of PCa (HR=0.64; 95% CI: 0.48-0.86), which was primarily driven by a frequency of LDA use equal to or higher than twice per week (HR=0.60; 95% CI: 0.43-0.83). Such an association was more pronounced (HR=0.43; 95% CI: 0.21-0.91) when LDA was used for five or more years. Our findings indicate that LDA use might be associated with a reduction of risk of PCa in patients with cardio- or cerebrovascular diseases. What's new? Aspirin may reduce the risk of PCa, according to these new results. Previous work has shown that LDA, often prescribed for cardiovascular or cerebrovascular disease, reduces the incidence of colorectal cancer. To probe a possible connection with PCa, these authors undertook a large-scale, population based retrospective cohort study involving more than 13,000 participants. PCa struck less frequently among those taking LDA at least twice per week, particularly if they continued taking it for several years.
引用
收藏
页码:205 / 211
页数:7
相关论文
共 50 条
  • [41] Low-dose aspirin and risk of gastric and oesophageal cancer: A population-based study
    Garcia Rodriguez, L.
    Vora, P.
    Soriano-Gabarro, M.
    Cea Soriano, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 259 - 259
  • [42] The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study
    Huang, W-K
    Chiou, M-J
    Yu, K-H
    Lin, Y-C
    Yang, T-S
    Chen, J-S
    Kuo, C-F
    See, L-C
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (04) : 432 - 439
  • [43] Low-dose aspirin and survival from lung cancer: a population-based cohort study
    Mc Menamin, Una C.
    Cardwell, Chris R.
    Hughes, Carmel M.
    Murray, Liam M.
    BMC CANCER, 2015, 15
  • [44] Low-dose aspirin use and endometrial cancer mortality-a Danish nationwide cohort study
    Sperling, Cecilie D.
    Verdoodt, Freija
    Aalborg, Gitte L.
    Dehlendorff, Christian
    Friis, Soren
    Kjaer, Susanne K.
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2020, 49 (01) : 330 - 337
  • [45] Low-dose aspirin and survival from lung cancer: a population-based cohort study
    Úna C. Mc Menamin
    Chris R. Cardwell
    Carmel M. Hughes
    Liam M. Murray
    BMC Cancer, 15
  • [46] Reduced risk of cancer among low-dose aspirin users: Data from French health care databases
    Ajrouche, Aya
    De Rycke, Yann
    Dalichampt, Marie
    Zeitoun, David Messika
    Hulot, Jean-Sebastien
    Estellat, Candice
    Tubach, Florence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (09) : 1258 - 1266
  • [47] Editorial: risk of gastric and duodenal ulcers among new users of low-dose aspirin
    Yeomans, Neville D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (02) : 334 - 335
  • [48] Incident cancer risk after the start of aspirin use: Results from a Dutch population-based cohort study of low dose aspirin users
    Hollestein, Loes M.
    van Herk-Sukel, Myrthe P. P.
    Ruiter, Rikje
    de Vries, Esther
    Mathijssen, Ron H. J.
    Wiemer, Erik A. C.
    Stijnen, Theo
    Coebergh, Jan-Willem W.
    Lemmens, Valery E. P. P.
    Herings, Ron M. C.
    Stricker, Bruno H. C.
    Nijsten, Tamar
    INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (01) : 157 - 165
  • [49] LOW-DOSE ASPIRIN USE ASSOCIATED WITH LOWER OVARIAN CANCER RISK
    Rosenberg, Karen
    AMERICAN JOURNAL OF NURSING, 2019, 119 (01) : 50 - 50